Previous 10 | Next 10 |
Dicerna Pharmaceuticals ([[DRNA]] +3.3%) announces positive preliminary data from a Phase 3 clinical trial, PHYOX3, evaluating once-monthly RNAi therapeutic nedosiran in patients with the three known types of primary hyperoxaluria (PH1, PH2 and PH3), a rare inherited disorder caused by excess...
– All Participants Receiving Nedosiran, Regardless of Subtype, Achieved Normalization or Near-Normalization of Urinary Oxalate, a Key PH Measure, by Day 180 in Ongoing, Open-Label Trial – – Nedosiran Was Generally Well Tolerated With No Serious Safety Conc...
Gainers: [[ARWR]] +12.0%. [[BKTI]] +9.3%. [[SNBR]] +8.8%. [[DRNA]] +4.5%. [[DRH]] +4.4%.Losers: [[FSLY]] -27.0%. [[LEAF]] -15.1%. [[VRTX]] -12.1%. [[NET]] -7.3%. [[DDOG]] -4.1%. For further details see: ARWR, SNBR, FSLY and NET among after-hours movers
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, w...
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming Chairman during 2021, at which time Bennett Shapiro, M.D., the current Chairman of t...
Aligos Therapeutics has filed terms to raise $150 million in an IPO. The firm is developing treatments for chronic Hepatitis B and other liver and viral diseases. ALGS has produced intriguing early stage results and the IPO is reasonably priced, so is worth considering for long-te...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the trea...
Takeda and Arrowhead agree to a partnership on Arrowhead's ARO-AAT, with Takeda getting U.S. co-promotion rights and exclusive ex-US rights. Arrowhead is getting $300 million upfront, up to $740 million in future milestone payments, U.S. co-promotion rights, and 20% to 25% royalties o...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Chardan...
– Biopharmaceutical Industry Veteran Brings Expertise in Global Drug Development and Corporate Governance – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid int...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...